Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

UCL vs UPC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UCL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–3 Matrix Metrics)

UCL Overall Winner 6-Pillar Tally: UCL 3 – 2 UPC (1 Tie) Matrix Metrics: UCL 6 – 3 UPC

As of Nov 20, 2026, uCloudlink Group Inc. (UCL) is the stronger overall head-to-head candidate over Universe Pharmaceuticals Inc. (UPC) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). UCL carries a Unified Composite Score of 50.0/100 (HOLD) at $0.21 (14.4x Forward P/E, -16.6% operating margin), whereas UPC carries 41.4/100 (SELL) at $1.08 (N/M Forward P/E, -11.8% operating margin).

  • Technical & Structure Timing Caution: UCL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5); meanwhile UPC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UCL vs UPC
UCL NASDAQ Head-to-Head Winner
uCloudlink Group Inc. American Depositary Shares
Communications Services, Nec
$0.21
-3.43% 1D
Market Cap $8.2M
TTM Revenue $79M
Forward P/E 14.4x
Beta / 30D Vol 0.73β · 129% Vol
Unified Composite Score
50.0 / 100 HOLD
Tech 67.0 Fund 61.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -24.6%), weak momentum, RSI 44
RSI-14: 43.5 · SMA20: $0.21 · SMA50: $0.27
UPC NASDAQ
Universe Pharmaceuticals Inc. Ordinary Shares
Pharmaceutical Preparations
$1.08
-20.59% 1D
Market Cap $6.8M
TTM Revenue $18M
Forward P/E N/M
Beta / 30D Vol 4.56β · 163% Vol
Unified Composite Score
41.4 / 100 SELL
Tech 25.0 Fund 53.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 22
RSI-14: 22.2 · SMA20: $1.60 · SMA50: $3.27

6-Pillar Scorecard Institutional Category Breakdown (UCL 3 – 2 UPC)

Columns: Metric · UCL · UPC
1. Valuation Multiples UCL
Forward P/E 14.4x N/M
Trailing P/E 14.4x N/M
PEG Ratio N/M N/M
EV / Revenue 0.1x 0.4x
2. Growth & Scale UCL
Revenue Growth (YoY) +1.1% -1.3%
Earnings Growth (YoY) +122.4% -82.0%
TTM Revenue (USD) $79M $18M
Market Cap $8.2M $6.8M
3. Profitability & Quality UPC
Gross Margin 50.8% 36.5%
Operating Margin -16.6% -11.8%
Net Profit Margin -12.6% -10.9%
Return on Equity (ROE) -36.3% -3.5%
4. Balance Sheet & Cash Flow UPC
Cash Generation (TTM) -$9.5M EBITDA -$1.6M EBITDA
Cash Flow Margin -12.1% EBITDA Mgn -9.1% EBITDA Mgn
Net Cash / Leverage $0.59 Book/Sh · -36.3% ROE $98.78 Book/Sh · -3.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat UCL
OpEx & R&D Intensity 67.4% of Rev ($53M) 48.3% of Rev ($8.6M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Telecom Services Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UCL (6) vs UPC (3)
Institutional Metric UCL UPC Criterion Row Edge
Market Capitalization
Scale
$8.2M $6.8M Larger Scale Tie
Trailing P/E Ratio
Valuation
14.4x N/M Lower Multiple UCL
Forward P/E Ratio
Valuation
14.4x N/M Lower Multiple UCL
Revenue Growth (YoY)
Growth
+1.1% -1.3% Higher Growth UCL
Operating Margin (TTM)
Profitability
-16.6% -11.8% Higher Margin UPC
Net Profit Margin
Profitability
-12.6% -10.9% Higher Margin UPC
Return on Equity (ROE)
Capital Efficiency
-36.3% -3.5% Higher ROE UPC
52-Week Range Position
Momentum
2% ($0–$3) 0% ($1–$18) Stronger Trend UCL
Beta / 30D Volatility
Risk Regime
0.73β · 129% Vol 4.56β · 163% Vol Lower Realized Risk UCL
Unified Institutional Score
Composite Signal
50.0 / 100 (HOLD) 41.4 / 100 (SELL) Higher Composite UCL
Trailing 12M Revenue (USD)
Operating Scale
$79M $18M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
50.8% 36.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · 0.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.5M EBITDA ($0.59 Book/Sh · -36.3% ROE) -$1.6M EBITDA ($98.78 Book/Sh · -3.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UCL +66.3 pp
UCL: -9.04% · UPC: -75.34%
3M Horizon UCL +36.27 pp
UCL: -43.58% · UPC: -79.85%
6M Horizon UPC +16.68 pp
UCL: -79.18% · UPC: -62.5%
1Y Horizon UPC +21.7 pp
UCL: -91.45% · UPC: -69.75%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UCL vs UPC. Trailing 12-month operating profitability (UCL -16.6% vs UPC -11.8%) and valuation multiples (UCL 14.4x vs UPC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

UCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$79M
Gross Margin50.8%
Op. Margin-16.6%
ROE / Fwd P/E-36.3% · 14.4x
UPC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$18M
Gross Margin36.5%
Op. Margin-11.8%
ROE / Fwd P/E-3.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UCL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UPC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UPC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UCL Moat Profile Cyclical / Execution-Driven Positioning
Telecom Services Operator
Competes within the Telecom Services value chain with $8.2M market capitalization and -16.6% operating margin.
OpEx & R&D Reinvestment 67.4% of Rev ($53M)
90D Engineering Disclosures 0 Published
UPC Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $6.8M market capitalization and -11.8% operating margin.
OpEx & R&D Reinvestment 48.3% of Rev ($8.6M)
90D Engineering Disclosures 0 Published

Investor FAQ UCL vs UPC Key Questions & Quantitative Answers

As of Nov 20, 2026, uCloudlink Group Inc. (UCL) is the stronger overall head-to-head candidate over Universe Pharmaceuticals Inc. (UPC) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). UCL carries a Unified Composite Score of 50.0/100 (HOLD) at $0.21 (14.4x Forward P/E, -16.6% operating margin), whereas UPC carries 41.4/100 (SELL) at $1.08 (N/M Forward P/E, -11.8% operating margin). Technical & Structure Timing Caution: UCL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5); meanwhile UPC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

UCL leads the Growth & Scale pillar: UCL posts +1.1% YoY revenue growth and +122.4% YoY earnings growth on $79M TTM revenue (50.8% gross margin, -16.6% operating margin), compared with UPC at -1.3% YoY revenue growth and -82.0% YoY earnings growth on $18M TTM revenue (36.5% gross margin, -11.8% operating margin). On trailing 12-month operating scale, UCL generates $79M in USD-normalized revenue versus $18M for UPC. In operating R&D and SG&A reinvestment, UCL deploys 67.4% of Rev ($53M) (0 90-day corporate R&D disclosures) versus 48.3% of Rev ($8.6M) (0 disclosures) for UPC.

UCL screens cheaper on headline valuation multiples. UCL trades at 14.4x Forward P/E, 14.4x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-12.1% EBITDA margin), whereas UPC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-9.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UCL (-36.3% ROE) versus UPC (-3.5% ROE) capital efficiency.

In options market volatility and institutional positioning, UCL carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.73β · 129% Vol realized risk). By comparison, UPC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.56β · 163% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.